Taejong Song1, Seok Ju Seong, Duk-Soo Bae, Jong-Hyeok Kim, Dong Hoon Suh, Keun-Ho Lee, Sang-Yoon Park, Taek Sang Lee. 1. *Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University; †Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine; ‡Department of Obstetrics and Gynecology, Asan Medical Center, University of Ulsan College of Medicine, Seoul; §Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam; ∥Department of Obstetrics and Gynecology, Seoul St Mary's Hospital, Catholic University of Korea, Seoul; ¶Gynecologic Cancer Branch and Center for Uterine Cancer, Research Institute and Hospital, National Cancer Center, Goyang; and #Department of Obstetrics and Gynecology, SMG-SNU Boramae Medical Center, Seoul, Republic of Korea.
Abstract
OBJECTIVE: The purpose of this study was to determine the prognostic factors in women with synchronous endometrial and ovarian cancers. METHODS: Medical records of 3240 patients with endometrial cancer who had undergone primary surgery were collected from 7 institutions and were retrospectively reviewed. The progression-free survival (PFS) and overall survival (OS) curves and rates were calculated using the Kaplan-Meier method. Multivariate analysis to determine independent prognostic factors was performed using the Cox regression model. RESULTS: The incidence of synchronous endometrial/ovarian cancer was 3.8% (123/3240 women). During the median follow-up period of 66 months, 33.3% and 26.1% of women developed recurrences and reported cancer-related deaths. The 5-year PFS and 5-year OS for all 123 women were 66.9% and 80.0%, respectively. In multivariate analysis, pretreatment CA-125 and tumor stage of the ovary showed prognostic significance about PFS (P = 0.043 and P = 0.027) and OS (P = 0.047 and P = 0.031), respectively. CONCLUSIONS: Pretreatment CA-125 and tumor stage of the ovary were independent prognostic factors for recurrence and survival.
OBJECTIVE: The purpose of this study was to determine the prognostic factors in women with synchronous endometrial and ovarian cancers. METHODS: Medical records of 3240 patients with endometrial cancer who had undergone primary surgery were collected from 7 institutions and were retrospectively reviewed. The progression-free survival (PFS) and overall survival (OS) curves and rates were calculated using the Kaplan-Meier method. Multivariate analysis to determine independent prognostic factors was performed using the Cox regression model. RESULTS: The incidence of synchronous endometrial/ovarian cancer was 3.8% (123/3240 women). During the median follow-up period of 66 months, 33.3% and 26.1% of women developed recurrences and reported cancer-related deaths. The 5-year PFS and 5-year OS for all 123 women were 66.9% and 80.0%, respectively. In multivariate analysis, pretreatment CA-125 and tumor stage of the ovary showed prognostic significance about PFS (P = 0.043 and P = 0.027) and OS (P = 0.047 and P = 0.031), respectively. CONCLUSIONS: Pretreatment CA-125 and tumor stage of the ovary were independent prognostic factors for recurrence and survival.
Authors: Yuxuan Wang; Lu Li; Christopher Douville; Joshua D Cohen; Ting-Tai Yen; Isaac Kinde; Karin Sundfelt; Susanne K Kjær; Ralph H Hruban; Ie-Ming Shih; Tian-Li Wang; Robert J Kurman; Simeon Springer; Janine Ptak; Maria Popoli; Joy Schaefer; Natalie Silliman; Lisa Dobbyn; Edward J Tanner; Ana Angarita; Maria Lycke; Kirsten Jochumsen; Bahman Afsari; Ludmila Danilova; Douglas A Levine; Kris Jardon; Xing Zeng; Jocelyne Arseneau; Lili Fu; Luis A Diaz; Rachel Karchin; Cristian Tomasetti; Kenneth W Kinzler; Bert Vogelstein; Amanda N Fader; Lucy Gilbert; Nickolas Papadopoulos Journal: Sci Transl Med Date: 2018-03-21 Impact factor: 17.956
Authors: Barbara Zegarska; Maciej Nowacki; Katarzyna Pietkun; Wojciech Jozwicki; Tomasz Nowikiewicz; Noor Y Al-Obaidi; Samy L Habib; Wojciech Zegarski Journal: Postepy Dermatol Alergol Date: 2017-08-02 Impact factor: 1.837
Authors: Anna Myriam Perrone; Giulia Girolimetti; Martina Procaccini; Lorena Marchio; Alessandra Livi; Giulia Borghese; Anna Maria Porcelli; Pierandrea De Iaco; Giuseppe Gasparre Journal: Int J Mol Sci Date: 2018-07-13 Impact factor: 5.923